| Alternative Name: | CYP3A1 |
| |
| Host: | Sheep |
| |
| Immunogen: | Synthetic peptide corresponding to a portion of C-terminal rat CYP3A1. |
| |
| UniProt ID: | P04800 |
| |
| Species reactivity: | Rat
|
| |
| Specificity: | Recognizes rat CYP3A1. Not suitable for use on human tissue. |
| |
| Applications: | IHC (FS), IHC (PS), WB
|
| |
| Blocking Peptide: | For Blocking peptide see Prod. No. BML-CP0331.
|
| |
| Formulation: | Liquid. Serum containing 0.01% sodium azide. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | Members of the cytochrome P-450 3A (CYP3A) sub-family catalyze the 6β-hydroxylation of testosterone, and the metabolism of a number of drugs such as cyclosporin A (Prod. No. BML-A195), and warfarin. They are inducible by glucocorticoids such as dexamethasome (Prod. No. BML-EI126) and by macrolide antibiotics such as erythromycin and pregnenolone 16α-carbonitrile (U-14975, PCN) (Prod. No. BML-S620). Rat CYP3A1 and CPY3A2 share 89% sequence similarity at the amino acid level and are predominantly located in the liver, principally in the centrilobular region. PCN induces CYP3A1 gene expresion in regions of the intestine, lung and kidney. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
